i-Base home
Search Menu
  • Home
  • HTB
  • 2022
  • February

HTB

February 2022

Contents

Editorial

  • HTB: no. 1/2 (January/February 2022)
  • i-Base appeal: please support i-Base with £5 or £10 a month

Conference reports

  • CROI 2022 to only be virtual: programme online

Antiretrovirals

  • US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine
  • Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent

Guidelines

  • BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections

Coinfections and complications

  • HIV-associated reductions in telomere length are stopped by effective ART

Resistance

  • Drug resistance profile of integrase inhibitors when treating HIV-2

Other news

  • EACS HIV Summer School 2022: Applications are open

COVID-19: investigational drugs

  • UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19

COVID-19: guidelines

  • IDSA update COVID-19 guidelines (January 2022)

Job vacancies

  • i-Base vacancy: HIV treatment advocate and information officer

PDFs

  • HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022)
  • HTB RSS

Early access

  • Doravirine studies at Glasgow 2022 6 February 2023
  • Pipeline studies at Glasgow 2022 6 February 2023
  • Long-acting cabotegravir/rilpivirine: Adverse events, implementation and PROMs 6 February 2023
  • Lenacapavir approved in the US for multidrug resistant HIV 6 February 2023
  • All early access reports

Current issues

  • February 2023
  • January 2023
  • December 2022
  • Back issues

Special report

  • Latest statistics on HIV in the UK: data for 2021 1 December 2022

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook
i-Base on Facebook